Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.

Publikation

Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.

Wissenschaftlicher Artikel/Review - 04.01.2024

Smith Eric Edward, Shoamanesh Ashkan, Xu Lizhen, Heenan Laura, Saad Feryal, Colorado Pablo, Chen Chih-Hao, Lemmens Robin, De Marchis Gian Marco, Caso Valeria, Masjuan Jaime, Hirano Teruyuki, Milanov Ivan, Campbell Bruce C V, Mas Jean-Louis, Connolly Stuart J, Mundl Hardi, Hart Robert G, Kägi Georg

Zitation

Smith E, Shoamanesh A, Xu L, Heenan L, Saad F, Colorado P, Chen C, Lemmens R, De Marchis G, Caso V, Masjuan J, Hirano T, Milanov I, Campbell B, Mas J, Connolly S, Mundl H, Hart R, Kägi G. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes. Stroke 2024; 55:392-402.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Stroke 2024; 55

Veröffentlichungsdatum

04.01.2024

eISSN (Online)

1524-4628

Seiten

392-402

Kurzbeschreibung/Zielsetzung

Exploratory analysis of the phase 2 PACIFIC-Stroke (Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-Non-Cardioembolic Stroke) randomized trial suggested that asundexian, an oral factor XIa inhibitor, prevents recurrent stroke and transient ischemic attacks in patients with atherosclerotic stroke. In this post hoc exploratory analysis, we hypothesized that asundexian would be more effective in patients enrolled with large, multiple, or cortical acute infarcts on magnetic resonance imaging than in patients enrolled with a single small subcortical acute infarct, and asundexian would prevent incident cortical covert infarcts.